Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized pharmacological treatment for broken heart (takotsubo) syndrome
2020-002708-38Phase 4Active
- Sponsor
- Institute of Medicine, University of Gothenburg
- Start
- Jun 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of adenosine, dipyridamole and apixaban in Takotsubo cardiomyopathy (TCM) and Acute Heart Failure (AHF) (4 arms), sponsored by Institute of Medicine, University of Gothenburg. Primary endpoints: Primary endpoint - adenosine + dipyridamole vs standard care and Primary endpoint - apixaban vs no antithrombotic. Started Jun 2020; status: active.
02
Drugs
adenosinedipyridamoleapixaban
03
Conditions
Takotsubo cardiomyopathy (TCM)Acute Heart Failure (AHF)
Beyond the preview
Go deeper on 2020-002708-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002708-38.